DYN
Neutral signalScored 2026-09-11 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Dyne Therapeutics, Inc.
- Nom
- Dyne Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $2.9B
- Employés
- 289
- PDG
- John G. Cox
- Site web
- https://www.dyne-tx.com
- Marché
- CAPRIONSLRMRPEPGPTCTSLDB
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 2 500 titres (~40 000,00 $ US) VENTE TOTALE: 5 658 titres (~106 823,04 $ US)
- Insiders
- Posner Brian SCox John
- Total bought
-
$40,000
Avg buy (VWAP, 90d window) $16.00 vs last close —
- Total sold
-
$472,865
Avg sell (VWAP, 90d window) $23.24 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$472,865 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-02
- Last synced
-
2026-10-08 10:07:03
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-02 | Posner Brian S | Buy · P | 2,500 | $16.00 | $40,000 | Form 4 |
| 2026-09-08 | Cox John | Sell · S · 10b5-1 | 5,658 | $18.88 | $106,823 | Form 4 |
| 2026-09-08 | Friedl-Naderer Johanna | Sell · S · 10b5-1 | 185 | $18.88 | $3,493 | Form 4 |
| 2026-09-08 | Kerr Douglas | Sell · S · 10b5-1 | 1,290 | $18.88 | $24,355 | Form 4 |
| 2026-09-04 | Friedl-Naderer Johanna | Sell · S · 10b5-1 | 900 | $24.35 | $21,915 | Form 4 |
| 2026-09-04 | Kerr Douglas | Sell · S · 10b5-1 | 3,745 | $24.35 | $91,191 | Form 4 |
| 2026-08-13 | Cox John | Sell · S · 10b5-1 | 4,986 | $26.28 | $131,032 | Form 4 |
| 2026-08-13 | Friedl-Naderer Johanna | Sell · S · 10b5-1 | 226 | $26.28 | $5,939 | Form 4 |
| 2026-08-13 | Kerr Douglas | Sell · S · 10b5-1 | 1,556 | $26.28 | $40,892 | Form 4 |
| 2026-08-13 | Lucera Erick | Sell · S · 10b5-1 | 1,797 | $26.28 | $47,225 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-11 Drivers: fundamentals. Moteurs : fondamentaux.
DYN presents a deeply unfavorable risk/reward profile: severe fundamental distress with zero revenue, persistent operating losses, and negative returns on both assets and equity undermine the superficially high…
The first sentence of the analysis written for DYN on 2026-09-11 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 22.25 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 22.254 | 15.601 | 2.532 | 9.456 | 13.313 | |
| Quick Ratio | 22.254 | 15.601 | 2.532 | 9.456 | 13.313 | |
| Solvency Ratio | -2.068 | -5.133 | -3.164 | -3.084 | -2.579 | |
| Cash Ratio | 17.647 | 10.305 | 2.380 | 6.129 | 6.992 | |
| Price To Earnings Ratio | -5.637 | -6.991 | -3.367 | -3.588 | -4.058 | |
| Price To Earnings Growth Ratio | -1.900 | 0.476 | -0.151 | -0.350 | -0.030 | |
| Forward Price To Earnings Growth Ratio | -1.900 | 0.476 | -0.151 | -0.350 | -0.030 | |
| Price To Earnings Diluted Ratio | -5.637 | -6.991 | -3.367 | -3.588 | -4.058 | |
| Price To Earnings Diluted Growth Ratio | -1.900 | 0.476 | -0.151 | -0.350 | -0.030 | |
| Price To Book Ratio | 2.584 | 3.522 | 8.695 | 2.387 | 1.644 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -6.201 | -7.525 | -4.202 | -3.844 | -4.913 | |
| Price To Operating Cash Flow Ratio | -6.231 | -7.586 | -4.219 | -3.921 | -5.061 | |
| Debt To Assets Ratio | 0.017 | 0.035 | 0.166 | 0.100 | 0.077 | |
| Debt To Equity Ratio | 0.021 | 0.038 | 0.300 | 0.121 | 0.089 | |
| Debt To Capital Ratio | 0.020 | 0.037 | 0.231 | 0.108 | 0.081 | |
| Long Term Debt To Capital Ratio | 0.015 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.221 | 1.097 | 1.808 | 1.214 | 1.156 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -7.965 | -6.919 | -3.683 | -5.470 | -4.163 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | 1.008 | 1.004 | 1.020 | 1.030 | |
| Debt Service Coverage Ratio | -39.150 | -64.985 | 0.000 | -56.050 | 0.000 | |
| Interest Coverage Ratio | -75.611 | 0.000 | 0.000 | -58.609 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -80.722 | -60.282 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -19.884 | -12.188 | -6.863 | -5.040 | -3.664 | |
| Capital Expenditure Coverage Ratio | -210.004 | -123.051 | -258.104 | -50.096 | -33.047 | |
| Dividend Paid And Capex Coverage Ratio | -210.004 | -123.051 | -258.104 | -50.096 | -33.047 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.743 | -5.732 | -2.996 | -2.818 | -2.948 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 22.254 | ▲6.652 | ▲9.622 |
| Quick Ratio | 22.254 | ▲6.652 | ▲9.622 |
| Solvency Ratio | -2.067 | ▲3.066 | ▲1.138 |
| Cash Ratio | 17.647 | ▲7.342 | ▲8.956 |
| Price To Earnings Ratio | -5.637 | ▲1.354 | ▼-0.909 |
| Price To Earnings Growth Ratio | -1.900 | ▼-2.376 | ▼-1.509 |
| Forward Price To Earnings Growth Ratio | -1.900 | ▼-2.376 | ▼-1.509 |
| Price To Earnings Diluted Ratio | -5.637 | ▲1.354 | ▼-0.909 |
| Price To Earnings Diluted Growth Ratio | -1.900 | ▼-2.376 | ▼-1.509 |
| Price To Book Ratio | 2.584 | ▼-0.937 | ▼-1.182 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -6.201 | ▲1.324 | ▼-0.864 |
| Price To Operating Cash Flow Ratio | -6.231 | ▲1.355 | ▼-0.827 |
| Debt To Assets Ratio | 0.017 | ▼-0.018 | ▼-0.062 |
| Debt To Equity Ratio | 0.021 | ▼-0.017 | ▼-0.093 |
| Debt To Capital Ratio | 0.020 | ▼-0.016 | ▼-0.075 |
| Long Term Debt To Capital Ratio | 0.015 | ▲0.015 | ▲0.012 |
| Financial Leverage Ratio | 1.221 | ▲0.123 | ▼-0.078 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -7.965 | ▼-1.046 | ▼-2.325 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | ▼-0.003 | ▼-0.009 |
| Debt Service Coverage Ratio | -39.150 | ▲25.834 | ▼-7.113 |
| Interest Coverage Ratio | -75.611 | ▼-75.611 | ▼-48.767 |
| Short Term Operating Cash Flow Coverage Ratio | -80.722 | ▼-20.440 | ▼-52.521 |
| Operating Cash Flow Coverage Ratio | -19.884 | ▼-7.696 | ▼-10.356 |
| Capital Expenditure Coverage Ratio | -210.004 | ▼-86.953 | ▼-75.143 |
| Dividend Paid And Capex Coverage Ratio | -210.004 | ▼-86.953 | ▼-75.143 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.743 | ▲1.989 | ▼-0.095 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.51B | $2.22B | $793.8M | $602.4M | $605.1M | |
| Enterprise value | $1.64B | $1.81B | $699.6M | $460.7M | $437.0M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -4.07x | -6.18x | -3.72x | -3.00x | -3.65x | |
| EV / Free cash flow | -4.05x | -6.13x | -3.70x | -2.94x | -3.55x | |
| EV / EBITDA | -3.74x | -5.73x | -3.00x | -2.82x | -2.95x | |
| Net debt / EBITDA | 1.99x | 1.31x | 0.40x | 0.87x | 1.14x | |
| Current ratio | 22.25x | 15.60x | 2.53x | 9.46x | 13.31x | |
| Income quality | 0.90x | 0.92x | 0.80x | 0.91x | 0.80x | |
| Graham net-net | $7 | $6 | $1 | $4 | $6 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 101.4% | 100.0% | 100.0% | 101.8% | 100.0% | |
| Working capital | $1.08B | $617.0M | $78.3M | $237.5M | $353.7M | |
| Invested capital | $1.12B | $647.0M | $111.7M | $275.9M | $394.6M | |
| Return on assets | -37.6% | -45.9% | -142.9% | -54.9% | -35.1% | |
| Operating ROA | -49.9% | -80.3% | -102.7% | -46.7% | -38.5% | |
| Return on tangible assets | -37.6% | -45.9% | -142.9% | -54.9% | -35.1% | |
| Return on equity | -45.9% | -50.4% | -258.4% | -66.6% | -40.5% | |
| Return on invested capital | -41.0% | -52.6% | -204.0% | -60.4% | -37.4% | |
| Return on capital employed | -41.2% | -53.0% | -212.4% | -61.4% | -37.8% | |
| Earnings yield | -17.8% | -14.3% | -29.7% | -27.9% | -24.7% | |
| Free cash flow yield | -16.1% | -13.3% | -23.8% | -26.0% | -20.4% | |
| Capex / Op. cash flow | -0.5% | -0.8% | -0.4% | -2.0% | -3.0% | |
| Capex / Depreciation | 93.7% | -123.0% | 43.6% | 182.2% | 332.5% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 1440d | 1068d | 3402d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -1440d | -1068d | -3402d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+13.3%EV / Sales n/aEV / EBITDA ▲+34.7%EV / Op. cash flow ▲+2.114Earnings yield ▼-0.035
Profitability
Return on equity ▲+0.045Return on assets ▲+0.083Return on invested capital ▲+0.116Return on capital employed ▲+0.118Operating ROA ▲+0.305Income quality ▼-0.017Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+371.868Operating cycle n/aCash conversion cycle ▼-371.868Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+6.652Net debt / EBITDA ▲+0.688Working capital ▲+458941000.000Invested capital ▲+473699000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+315.2%EV / Sales n/aEV / EBITDA ▼-26.9%EV / Op. cash flow ▼-0.411Earnings yield ▲+0.069
Profitability
Return on equity ▼-0.054Return on assets ▼-0.025Return on invested capital ▼-0.036Return on capital employed ▼-0.034Operating ROA ▼-0.113Income quality ▲+0.103Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+8.940Net debt / EBITDA ▲+0.859Working capital ▲+722293000.000Invested capital ▲+726104000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-09-29 Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12 months -
- 2026-09-17 Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 14 newly hired employees. The awards were made as an inducement material to the newly hired employees'' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-09-14 Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-09 Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class Dyne Therapeutics remains a Buy despite a 16% selloff triggered by Novartis'' DM1 trial failure, which heightened platform-wide clinical risk perceptions. The Novartis HARBOR trial failure challenges the core RNA-targeting therapeutic thesis, raising doubts about translating biomarker gains into functional benefit for DYN''s DM1 and DMD programs. DYN''s lead asset, z-rostudirsen, faces regulatory and confirmatory risks, with FDA approval likely but long-term value now more uncertain due to functional outcome concerns.
- 2026-09-09 Stock Traders Buy High Volume of Dyne Therapeutics Call Options (NASDAQ:DYN) Dyne Therapeutics, Inc. (NASDAQ: DYN - Get Free Report) saw unusually large options trading activity on Tuesday. Stock investors bought 20,532 call options on the stock. This is an increase of 4,325% compared to the average volume of 464 call options. Insider Activity In other Dyne Therapeutics news, CEO John Cox sold 5,658 shares of the
- 2026-09-08 Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling Dyne Therapeutics Inc. (NASDAQ:DYN) stock is trading lower on Tuesday in reaction to Novartis AG''s (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1).
- 2026-09-08 Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose portion of the trial to be compared against a matched natural history cohort -
- 2026-09-04 Dyne Therapeutics, Inc. $DYN is Atlas Venture Life Science Advisors LLC’s 2nd Largest Position Atlas Venture Life Science Advisors LLC trimmed its stake in shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) by 25.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,800,099 shares of the company''s stock after selling 2,330,366 shares during the
- 2026-09-03 Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting - Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), which is under FDA review for exon 51 DMD - WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it will present preclinical data supporting the ongoing development of DYNE-253, DYNE-245, DYNE-244 and DYNE-255 for the potential treatment of DMD amenable to skipping of exons 53, 45, 44 and 55, respectively, at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting being held September 25-27, 2026, in San Antonio, TX.
- 2026-09-02 Dyne Therapeutics to Participate in Upcoming Investor Conferences WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: